Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses

Shelley, Mike; Mason, Malcolm David; Kynaston, Howard

doi:10.1016/j.ctrv.2009.12.005

Cited by 145 publications

(96 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 Even though new treatments have been reported, more results and larger studies are needed. 6,12,[14][15][16] Colombo and colleagues found that C-HT is more effective than MMC alone. 17 The 10-year disease-free survival rate for C-HT and MMC alone were 53% and 15%, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer

Ekin¹,

Akarken

Zorlu³

et al. 2015

CUAJ

View full text Add to dashboard Cite

Introduction: Patients with high-risk non-muscle invasive bladder cancer (NMIBC) need adjuvant intravesical treatment after surgery. Although bacillus Calmette-Guérin (BCG) is highly effective, new adjuvant treatments to decrease recurrences and toxicity have been studies. We performed a retrospective propensity score-matched study to compare the efficacy of BCG and chemohyperthermia (C-HT). Methods: We included 1937 patients diagnosed with bladder cancer between January 2004 and January 2014. The primary efficacy endpoint was recurrence-free interval. Patients treated with C-HT were matched with patients treated with BCG using propensity score-matched analysis. Cox-regression models were used to estimate the association between intravesical treatments and the presence of recurrence and progression. Results: Of the 710 patients treated with intravesical treatments, 40 and 142 were eligible for inclusion in C-HT and BCG groups, respectively. Following case matching, there were no differences in patient or tumour characteristics between treatment groups. The 2-year recurrence-free interval in C-HT and BCG groups were 76.2% and 93.9%, respectively (p = 0.020). C-HT treatment (hazard ratio [HR] 5.42; 95% confidence interval [CI] 1.11-26.43; p = 0.036) and high-grade tumour (HR 4.60; 95% CI 1.01-20.88; p = 0.048) are associated with an elevated odds of tumour recurrence. In multivariate Cox-regression analysis, there was no significant difference between C-HT and BCG in the odds of recurrence (p = 0.054). There were no differences in progression between C-HT and BCG. Conclusion: C-HT is not as effective treatment as BCG in high-risk NMIBC patients who are BCG-naive. Although, there were no significant difference in the odds of recurrence, recurrence-free interval is significantly improved by the administration of BCG.

show abstract

Section: Discussionmentioning

confidence: 99%

“…3 Intravesical BCG prevents 31% to 50% of tumour recurrence, compared to TUR alone. 12 However, the side effects of BCG are remarkable, and the treatment discontinuation rate of BCG for toxicity is 7% to 19%. 13 In a meta-analysis, a 32% reduction in tumour recurrence for BCG maintenance compared to MMC was found.…”

Section: Discussionmentioning

confidence: 99%

Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer

Ekin¹,

Akarken

Zorlu³

et al. 2015

CUAJ

View full text Add to dashboard Cite

show abstract

“…5 The non-invasive papillary tumors and non-invasive in situ UCs are typically treated with the installation of intraluminal (intravesical) chemotherapy and immunotherapy. [6][7][8][9] Although this approach controls the disease in most patients for long periods of time, many patients ultimately experience disease progression heralded by both transformation of the tumor from low grade to high grade and the development of muscle-invasive disease. 6 Both patients who experience disease progression and the patients who initially present with muscle-invasive UC are most often treated surgically by either partial or total cystectomies.…”

mentioning

confidence: 99%

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

Wang²,

et al. 2014

View full text Add to dashboard Cite

Although urothelial carcinoma (UC) of the urinary bladder generally portends a favorable prognosis, metastatic tumors often follow an aggressive clinical course. DNA was extracted from 40 lm of formalin-fixed, paraffinembedded (FFPE) sections from 35 stage IV UCs that had relapsed and progressed after primary surgery and conventional chemotherapy. Next-generation sequencing (NGS) was performed on hybridization-captured, adaptor ligation-based libraries for 3320 exons of 182 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer to at an average sequencing depth of 1164 Â and evaluated for all classes of genomic alterations (GAs). Actionable GAs were defined as those impacting the selection of targeted anticancer therapies on the market or in registered clinical trials. A total of 139 GAs were identified, with an average of 4.0 GAs per tumor (range 0-10), of which 78 (56%) were considered actionable, with an average of 2.2 per tumor (range 0-7). Twenty-nine (83%) cases harbored at least one actionable GA including: PIK3CA (9 cases; 26%); CDKN2A/B (8 cases; 23%); CCND1 (5 cases; 14%); FGFR1 (5 cases; 14%); CCND3 (4 cases; 11%); FGFR3 (4 cases; 11%); MCL1 (4 cases; 11%); MDM2 (4 cases; 11%); EGFR (2 cases, 6%); ERBB2 (HER2/neu) (2 cases, 6%); NF1 (2 cases, 6%) and TSC1 (2 cases, 6%). Notable additional alterations included TP53 (19 cases, 54%) and RB1 (6 cases; 17%). Genes involved in chromatin modification were altered by nonsense mutation, splice site mutation or frameshift indel in a mutually exclusive manner in nearly half of all cases including KDM6A (10 cases; 29%) and ARID1A (7 cases; 20%). Comprehensive NGS of 35 UCs of the bladder revealed a diverse spectrum of actionable GAs in 83% of cases, which has the potential to inform treatment decisions for patients with relapsed and metastatic disease.

show abstract

“…High-risk disease of NMIBC revealed high rates (up to 90%) of recurrence (Shelley et al, 2010). It is important to diagnose UCB accurately and quickly with the help of a simple and cost-effective method.…”

Section: Discussionmentioning

confidence: 99%

“…Approximately 75% of UCB cases are diagnosed as nonmuscle-invasive bladder cancer (NMIBC) at the first diagnosis (Shelley et al, 2010). NMIBC has the tendency to recur and may progress to muscle-invasive bladder cancer (MIBC), which is a life-threatening neoplasm .…”

Section: Introductionmentioning

confidence: 99%

Serum Periplakin as a Potential Biomarker for Urothelial Carcinoma of the Urinary Bladder

Matsumoto¹,

Ikeda²,

Matsumoto³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The objectives of this study were to examine serum periplakin expression in patients with urothelial carcinoma of the urinary bladder and in normal controls, and to examine relationships with clinicopathological findings. Detection of serum periplakin was performed in 50 patients and 30 normal controls with anti-periplakin antibodies using the automatic dot blot system, and a micro-dot blot array with a 256 solid-pin system. Levels in patients with urothelial carcinoma of the urinary bladder were significantly lower than those in normal controls (0.31 and 5.68, respectively; p<0.0001). The area under the receiver-operator curve level for urothelial carcinoma of the urinary bladder was 0.845. The sensitivity and specificity, using a cut-off point of 4.045, were 83.7% and 73.3%, respectively. In addition, serum periplakin levels were significantly higher in patients with muscle-invasive cancer than in those with nonmuscle-invasive cancer (P = 0.03). In multivariate Cox proportional hazards regression analysis, none of the clinicopathological factors was associated with an increased risk for progression and cancer-specific survival. Examination of the serum periplakin level may play a role as a noninvasive diagnostic modality to aid urine cytology and cystoscopy.

show abstract

Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses

Cited by 145 publications

References 63 publications

Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer

Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

Serum Periplakin as a Potential Biomarker for Urothelial Carcinoma of the Urinary Bladder

Contact Info

Product

Resources

About